Equillium, Inc. (NASDAQ:EQ - Get Free Report) has been given a consensus rating of "Moderate Buy" by the twelve ratings firms that are covering the firm, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, eight have given a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $7.12.
A number of equities research analysts have commented on EQ shares. Leerink Partners assumed coverage on Equillium in a research note on Monday, October 12th. They issued an "outperform" rating and a $6.00 price objective for the company. Roth Capital reaffirmed a "buy" rating on shares of Equillium in a research report on Monday, October 26th. Raymond James Financial reiterated a "strong-buy" rating on shares of Equillium in a report on Friday. Jefferies Financial Group set a $4.00 price target on shares of Equillium and gave the company a "buy" rating in a research report on Friday. Finally, Zacks Research upgraded shares of Equillium from a "strong sell" rating to a "hold" rating in a research note on Tuesday, August 11th.
Get Our Latest Stock Report on Equillium
Equillium Price Performance
EQ stock opened at $1.21 on Wednesday. The stock has a market capitalization of $99.61 million, a PE ratio of -6.72 and a beta of 2.08. The company's 50-day moving average is $1.54 and its 200-day moving average is $2.08. Equillium has a 1 year low of $0.81 and a 1 year high of $3.54.
Equillium (NASDAQ:EQ - Get Free Report) last issued its earnings results on Thursday, November 12th. The company reported ($0.04) EPS for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. On average, analysts anticipate that Equillium will post -0.20 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Janus Henderson Group PLC raised its holdings in shares of Equillium by 10.8% in the 1st quarter. Janus Henderson Group PLC now owns 6,494,571 shares of the company's stock worth $12,957,000 after acquiring an additional 632,359 shares during the last quarter. Jupiter Topco LLC bought a new position in Equillium in the 2nd quarter valued at about $20,685,000. Aberdeen Group plc lifted its position in Equillium by 22.8% in the 3rd quarter. Aberdeen Group plc now owns 4,458,351 shares of the company's stock valued at $7,245,000 after acquiring an additional 826,692 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in Equillium in the 2nd quarter valued at about $12,027,000. Finally, Eversept Partners LP acquired a new position in Equillium during the 1st quarter valued at about $2,998,000. 27.05% of the stock is owned by institutional investors.
Equillium Company Profile
(
Get Free Report)
Equillium is a biotechnology company focused on developing medicines that target immune pathways involved in autoimmune and inflammatory diseases. Its research has centered on treatments for conditions with significant unmet medical needs. The company's leading program has been itolizumab, a monoclonal antibody that targets CD6, an immune-cell protein. Equillium obtained development and commercialization rights to itolizumab from India-based Biocon for several markets, including the United States, Canada, Australia and New Zealand.
Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Equillium, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Equillium wasn't on the list.
While Equillium currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.